TY - JOUR
T1 - hsa-miR-346 is a potential serum biomarker of Mycobacterium avium complex pulmonary disease activity
AU - Nishimura, Tomoyasu
AU - Tamizu, Eiko
AU - Uno, Shunsuke
AU - Uwamino, Yoshifumi
AU - Fujiwara, Hiroshi
AU - Nishio, Kazumi
AU - Nakano, Yasushi
AU - Shiono, Hirofumi
AU - Namkoong, Ho
AU - Hoshino, Yoshihiko
AU - Iwata, Satoshi
AU - Hasegawa, Naoki
N1 - Funding Information:
The authors thank the healthy subjects who volunteered for this study, and Dr. Takemasa Takii for the generous gift of the M. avium strain 104. The authors are grateful to Dr. Heinz G. Remold from the Brigham and Women's Hospital at Harvard Medical School (MA, USA) for his critical reading of our manuscript. This work was supported by the Japan Society for the Promotion of Science [KAKENHI 16K09942 to T.N. and 25461520 and 16K09941 to N.H.], the Daiwa Securities Health Foundation [T.N.], and the Kurozumi Medical Foundation [T.N.].
Publisher Copyright:
© 2017 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
PY - 2017/10
Y1 - 2017/10
N2 - MicroRNA (miRNA) has been recently recognized as a biomarker of various diseases; however, there are no known miRNAs associated with Mycobacterium avium complex (MAC) pulmonary disease. In addition, there are no known biomarkers to precisely reflect disease activity after the diagnosis of MAC pulmonary disease. Thus, we sought to identify a miRNA which is a candidate biomarker of MAC pulmonary disease activity. Serum hsa-miR-346 concentrations of 16 patients with M. avium pulmonary disease were significantly higher than those of 16 healthy controls (p = 0.047). The secretion of hsa-miR-346 increased in a multiplicity of infection-dependent manner in M. avium-infected macrophages. Serum hsa-miR-346 levels of 5 patients with bacterial conversion at the end of follow-up were significantly lower than those at the beginning of the follow-up (p = 0.043). In addition, the longitudinal change in serum hsa-miR-346 concentration correlated with bacterial load in 2 patients with M. avium pulmonary disease. Based on our results, it is supposed that MAC-infected macrophages in pulmonary lesions produce hsa-miR-346, which is then secreted into the bloodstream. The magnitude of this process could be quantitatively controlled by the bacterial load, suggesting that serum hsa-miR-346 is a potentially useful biomarker of MAC pulmonary disease activity.
AB - MicroRNA (miRNA) has been recently recognized as a biomarker of various diseases; however, there are no known miRNAs associated with Mycobacterium avium complex (MAC) pulmonary disease. In addition, there are no known biomarkers to precisely reflect disease activity after the diagnosis of MAC pulmonary disease. Thus, we sought to identify a miRNA which is a candidate biomarker of MAC pulmonary disease activity. Serum hsa-miR-346 concentrations of 16 patients with M. avium pulmonary disease were significantly higher than those of 16 healthy controls (p = 0.047). The secretion of hsa-miR-346 increased in a multiplicity of infection-dependent manner in M. avium-infected macrophages. Serum hsa-miR-346 levels of 5 patients with bacterial conversion at the end of follow-up were significantly lower than those at the beginning of the follow-up (p = 0.043). In addition, the longitudinal change in serum hsa-miR-346 concentration correlated with bacterial load in 2 patients with M. avium pulmonary disease. Based on our results, it is supposed that MAC-infected macrophages in pulmonary lesions produce hsa-miR-346, which is then secreted into the bloodstream. The magnitude of this process could be quantitatively controlled by the bacterial load, suggesting that serum hsa-miR-346 is a potentially useful biomarker of MAC pulmonary disease activity.
KW - Macrophage
KW - MicroRNA
KW - Mycobacterium avium complex
UR - http://www.scopus.com/inward/record.url?scp=85027684734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027684734&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2017.07.015
DO - 10.1016/j.jiac.2017.07.015
M3 - Article
C2 - 28827075
AN - SCOPUS:85027684734
SN - 1341-321X
VL - 23
SP - 703
EP - 708
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 10
ER -
